Board of Directors
Meet our Board of Directors
Etiometry’s Board of Directors is comprised of seasoned leaders from the worlds of healthcare, investment, and technology. United by a shared commitment to innovation and patient impact, they bring decades of experience in company building, strategic investing, and health system leadership. Together, they help guide Etiometry’s mission to materially improve critical care delivery through its AI-based clinical intelligence platform.
Greg Martin
President and CEO, Shamrock Holdings, Inc.
Greg Martin is the President and CEO of Shamrock Holdings, Inc., a diversified investment firm owned by members of the Disney family. In addition to leading Shamrock, he serves on the company’s Board of Directors and is an active member of the Roy and Patricia Disney Family Foundation’s Investment Committee. Greg is passionate about working with forward-thinking companies and currently lends his expertise as a board member to several innovative organizations, including Ionetix Corp., Etiometry, Inc., Cadence OTC, Evolved by Nature, Inc., and Integrated Realty Capital, LLC. With a career that spans strategic investing, company building, and long-term value creation, Greg brings both insight and a collaborative spirit to every table he sits at. He’s known for his thoughtful approach, deep commitment to mission-driven enterprises, and his ability to connect vision with execution.
David Shepherd
Owner and Managing Board Member at SKK
David is the Founder and a Managing Partner of Shepherd Kaplan Krochuk, an advisory firm and merchant bank serving institutions and family offices. With a career spanning 30 years in finance, he leads the capital formation efforts of the firm and provides strategic guidance to emerging companies in the technology and life sciences sectors. David is a strategic advisor to institutions and family offices, focusing on structuring and portfolio management, as well as reporting and governance regimes. He currently holds board positions at Etiometry Inc, Cristcot LLC, NanoDx Inc, ARQA AI, and Envirokure Inc, while also serving on the advisory boards of Terawave LLC and Global AI. David co-chairs the firm's Investment Committee and FinTech development efforts at SKK.
Guy Fish, MD, MBA
Chief Executive Officer of Codman Square Health Center
Dr. Guy Fish, MD, MBA, is the Chief Executive Officer of Codman Square Health Center, where he leads efforts to provide high-quality, community-based care in Boston. He brings over 25 years of experience in healthcare leadership, innovation, and strategy. Prior to joining Codman Square, he served as CEO of Greater Lawrence Family Health Center, and held leadership roles at Cellanyx Diagnostics, a company using AI to guide cancer treatment, and Next Stage Therapeutics in Spain. Earlier in his career, Dr. Fish spent 17 years at Fletcher Spaght, Inc., advising health care companies and investors on market strategy, growth, and innovation across medtech, diagnostics, biotech, and digital health. He also helped manage two healthcare venture funds through Fletcher Spaght Ventures. He began his career as a practicing internist serving rural and underserved populations and has held roles in equity research and business development in the medical technology sector. A Cleveland native, Dr. Fish holds a biochemistry degree from Harvard, a medical degree from Yale, and an MBA from Yale School of Management. He is a trustee of Beth Israel Deaconess Medical Center, an executive board member of Community Care Cooperative, and a founding member of the Massachusetts Health Equity Compact. Dr. Fish is committed to advancing health equity, innovation, and culturally responsive care.
Shane Cooke
President & Chief Executive Officer
Shane Cooke joined Etiometry in 2019 as President & CEO, bringing over 20 years of experience in the medical device and pharmaceutical market spaces in a variety of sales, marketing, strategy and portfolio management roles. Before joining Etiometry, Shane spent 5+ years as Chief Strategy Officer of Cheetah Medical, which was acquired by Baxter International in 2019. Prior to Cheetah, Shane spent 11 years with Covidien in the patient care, vascular therapies and corporate sectors, with positions such as: corporate strategy, market and competitive intelligence, leading the market development center of excellence and leading strategy efforts for Japan, Europe, Australia and Canada. Shane holds a BA in psychology from the University of Rochester, as well as an MBA from Suffolk University.
Dimitar Baronov, PhD
Chief Technology Officer and Co-Founder
Dimitar Baronov is a co-founder of Etiometry and leads the company’s research and development organization. He received his Bachelor’s degree from Technical University in Sofia, Bulgaria and a Ph.D. in Aerospace Engineering from Boston University. Before co-founding Etiometry, Dimitar developed a theory for optimal human-machine interaction in achieving complex tasks. This work informed the U.S. Air Force, and provides a basis for Etiometry’s innovative approach to integrating analytics into medical care. As CTO of Etiometry, Dimitar is the lead designer of the Etiometry Platform that quantifies clinical risks based on continuous streams of physiologic data. He has also served as the Principal Investigator for several National Institute of Health grants.